139 related articles for article (PubMed ID: 30062555)
1. Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.
Saito K; Ikeda M; Kojima Y; Hosoi H; Saito Y; Kondo S
Cancer Chemother Pharmacol; 2018 Oct; 82(4):677-684. PubMed ID: 30062555
[TBL] [Abstract][Full Text] [Related]
2. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
3. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
Naganuma A; Hoshino T; Ohno N; Ogawa Y; Murakami T; Horiguchi S; Uehara D; Suzuki Y; Hatanaka T; Kudo T; Ishihara H; Sato K; Kakizaki S; Takagi H
In Vivo; 2019; 33(1):155-161. PubMed ID: 30587616
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.
Ai L; Xu Z; Yang B; He Q; Luo P
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1121-1127. PubMed ID: 31679411
[No Abstract] [Full Text] [Related]
5. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot skin reaction induced by sorafenib in a hepatocellular carcinoma patient.
Pathania YS
Postgrad Med J; 2020 Aug; 96(1138):495. PubMed ID: 31551240
[No Abstract] [Full Text] [Related]
7. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
8. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
[TBL] [Abstract][Full Text] [Related]
9. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
10. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
[TBL] [Abstract][Full Text] [Related]
11. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Lien RY; Tung HH; Wu SL; Hu SH; Lu LC; Lu SF
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1532. PubMed ID: 34910380
[TBL] [Abstract][Full Text] [Related]
12. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
15. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
16. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.
Wang E; Xia D; Bai W; Wang Z; Wang Q; Liu L; Wang W; Yuan J; Li X; Chen H; Lv Y; Niu J; He C; Guo W; Yin Z; Luo B; Han N; Wang Z; Yu T; Yuan X; Li K; Tie J; Li C; Cai H; Xia J; Fan D; Han G
Invest New Drugs; 2019 Jun; 37(3):401-414. PubMed ID: 30019101
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
18. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
[TBL] [Abstract][Full Text] [Related]
19. Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Ogawa C; Morita M; Omura A; Noda T; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Tsutsui A; Senoh T; Nagano T; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kokudo Y; Minami Y; Ueshima K; Sakurai T; Nishida N; Kudo M
Oncology; 2017; 93 Suppl 1():113-119. PubMed ID: 29258090
[TBL] [Abstract][Full Text] [Related]
20. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Iida-Ueno A; Enomoto M; Uchida-Kobayashi S; Hagihara A; Teranishi Y; Fujii H; Morikawa H; Murakami Y; Tamori A; Thuy LTT; Kawada N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):857-864. PubMed ID: 30178114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]